The effect of methionine on the uptake, distribution, and binding of the convulsant methionine sulfoximine (MSO) in 7 rat brain regions, the spinal cord, the liver, and the kidney was investigated. The administration of methionine decreased the uptake of MSO in all brain regions. The uptake of MSO by and its distribution in the nervous tissue was uniform and failed to result in any preferential accumulation of the drug. Methionine decreased the amount of MSO bound to cerebral structures and to the spinal cord. MSO bound to the spinal cord was less susceptible to release by Triton X-100 than was brain-bound MSO.
INTRODUCTION
For several years, various approaches have been used in an attempt to elucidate the mechanism of action of the convulsant L-methionine-dlsulfoximine (MSO). These have included studies on the effect of MSO on the cerebral metabolism of amino acids and ammonia (1-8), brain amines (9, 10), glycogen ( cortical slices (19) , rat brain S-adenosyl-L-methionine levels (20) , mouse cerebellar ammonia (7), and rat brain glutamine synthetase (3). MSO and methionine have also been shown to be uptake antagonists (21, 22) . We have investigated the effect of methionine on the uptake, distribution and binding of [3H]MSO in 7 brain regions, the spinal cord, the liver, and the kidney of the adult rat. We also attempted to establish whether methionine antagonizes MSO by disallowing MSO to reach its nervous tissue targets in sufficiently high amounts to elicit seizures.
EXPERIMENTAL PROCEDURE
Animals and Drug Treatment. Adult male Sprague-Dawley rats weighing 100-160 g were used throughout the study. A mixture of nonradioactive (Sigma Chemical Co., St. Louis, Missouri) and radioactive MSO (0.94 mmol/kg) was administered intraperitoneally alone or jointly with L-methionine (4.7 mmol/kg) (ICN Biochemicals, Cleveland, Ohio) in a total volume of 10 ml/kg in saline. The animals were sacrificed 1, 3, or 6 hr later, i.e., well before (1 and 3 hr) the onset of the seizure, or immediately preceding it (6 hr).
Purification of [3H]MSO.
Methyl tritiated MSO (5.1 mCi/mmol), purified as previously described (23) , was chromatographer on cellulose thin-layer-chromatography (TLC) plates (EM Laboratories, Elmsford, New York) in n-butanol, glacial acetic acid, and water (2:1:1), where it migrated identically with authentic nonradioactive MS O. Its final specific radioactivity was 3.67 mCi/mmol. Solutions of [aH]MSO were diluted for injection with nonradioactive MSO to achieve specific radioactivities of about 0.4 mCi/mmol.
Preparation of Tissue.
To minimize the contribution of circulating [3H]MSO to the estimation of the tissue radioactivity, animals were perfused immediately prior to sacrifice with either ice-cold 0.1 M sodium phosphate buffer, pH 7.4, or buffer containing 17 rag/ liter of nonradioactive MSO. As shown in Table I , identical results were achieved, indicating that the presence of MS 9 in the perfusing medium had no effect on the measurement of the tissue stores of [3H]MSO. Per-fusion was for 5 rain, i.e., until the perfusate was totally discolored. After perfusion, the brains were removed and dissected (24) into cerebellum (CL), brainstem (BS), striatum (ST), hypothalamus (HY), midbrain (MB), hippocampus (HI), and cerebral cortex (CX). The spinal cord, liver, and kidneys were also removed and, along with the brain regions, were weighed and homogenized in 10 vol of ice-cold 0.32 M sucrose. The homogenates were centrifuged at 100,000 g for 70 rain. The resulting pellet was washed with an equal volume of sucrose and the suspension was centrifuged as above yielding the "sucrose supernatant." The washed "sucrose pellet" was homogenized in an equal volume of Triton X-100 (0.02%) (w/v) (Sigma Chemical Co.) and was centrifuged as above yielding a "Triton supernatant" and a "Triton pellet" which was homogenized in ice-cold deionized water.
Determination of Radioactivity. Afiqnots of the whole homogenate, the "sucrose supernatant," the "Triton supernatant," and of the final "Triton pellet" suspension were digested in I ml of 2 N NaOH at 65~ for 16 hr. Samples were neutralized with 0. 
RESULTS

Uptake of [3H]MSO by Tissues
There were no significant differences between MSO and MSO + methionine-treated rats in any of the brain regions at 1 hr (Figure 1 
Regional Distribution of [ZH]MSO in Rat Brain
Only the cortex showed a sharp increase in its share of the total tissue 
Effect of Methionine on [3H]MSO Binding
Effect of Triton X-IO0 on MSO Release
Triton X-I00 homogenization (see Experimental Procedure) released all of the bound [3H]MSO (Table II) The accumulation of [~H]MSO in the brain regions ( Figure 3 ) was, in general, directly proportional to their weights. There was, however, a shift in the regional partition of [aH]MSO with time, as evidenced by its marked increase, between 1 and 3 hr, in the cortex and its parallel decrease in the cerebellum, the midbrain, the brainstem, and the hippocampus. It is of particular interest that the administration of methionine altered the time course of the regional partition of [3H]MSO for, under these conditions, the drug reached high cortical levels at 1 hr, but, by 3 hr, appeared to decay and accumulate instead in the cerebellum and the hippocampus. Although quantitatively much inferior, the binding of [3H]MSO in brain appeared tighter when the drug was given with methionine (Tables  II and liD , rather than alone, a phenomenon briefly noted before (22) . An increase in Triton-resistant [3H]MSO binding in the peripheral organs with time was also noted, and this occurred after administering [3H]MSO by itself and with methionine (Table III) .
[35S]MSO binding in mouse brain and liver was previously reported by Rao and Meister (26) who identified the presumably protein-bound radioactivity as MSO phosphate. We have heretofore failed to demonstrate soluble MSO metabolites in rat brain (22, 25) . Moreover, more recently we conducted a number of chromatographic experiments using a variety of organ extracts of [3H]MSO-treated rats and uncovered no evidence for the existence of soluble [3H]MSO metabolites.
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